Gemcitabine in soft tissue or bone sarcoma resistant to standard chemotherapy: a phase II study

  title={Gemcitabine in soft tissue or bone sarcoma resistant to standard chemotherapy: a phase II study},
  author={Ofer Merimsky and Isaac Meller and Gidon Flusser and Yehuda Kollender and Josephine Issakov and Miriam Weil-Ben-Arush and Eyal Fenig and Gad Neuman and Dov Sapir and Shmuel Ariad and Moshe Josef Inbar},
  journal={Cancer Chemotherapy and Pharmacology},
Purpose: To assess the efficacy of gemcitabine in patients with a variety of sarcomas that have failed to respond or escaped Adriamycin- and ifosfamide-based chemotherapy. Patients and methods: A group of 18 symptomatic heavily pretreated patients with sarcomas of bone or soft tissue received one induction course of gemcitabine at a dose of 1000 mg/m2 per week for 7 consecutive weeks, followed by 1 week rest. Response to the induction course was assessed by interview and by repeated ancillary… CONTINUE READING
38 Citations
9 References
Similar Papers


Publications citing this paper.
Showing 1-10 of 38 extracted citations


Publications referenced by this paper.
Showing 1-9 of 9 references

Preliminary results of a two-arm phase 2 trial of gemcitabine (Gem) in patients (Pts) with gastrointestinal leiomyosarcoma and other soft tissue sarcomas (STS)

  • SR Patel, J Jenkins, +9 authors RS Benjamin
  • Proc Am Soc Clin Oncol
  • 1999
1 Excerpt

Gemcitabine in pretreated patients with advanced STS: preliminary results from a phase II trial

  • E Spith-Schwalbe, A Koschuth, R Grunewald, I Genvresse, K Possinger
  • Proc Am Soc Clin Oncol
  • 1998
1 Excerpt

Sarcoma of bones

  • MM Malawer, MP Link, SS Donaldson
  • Cancer : principles and practice of oncology
  • 1997
1 Excerpt

Quality of life matters ! News section

  • BJ Braakhuis, E Boven, G Veerman, GJ Peters
  • Ann Oncol
  • 1995

Similar Papers

Loading similar papers…